Analysts think ENTO stock price could increase by 5146%
Aug 01, 2024, 6:26 AM
-41.28%
What does ENTO do
First Wave BioPharma Inc, based in Boca Raton, Florida, is a clinical-stage biopharmaceutical company focusing on developing non-systemic therapies for gastrointestinal diseases, including adrulipase and niclosamide. Since its IPO in 2016, the company employs 10 people and conducts Phase 2 clinical trials for treatments targeting cystic fibrosis, chronic pancreatitis, and coronavirus-related GI infections.
3 analysts think ENTO stock price will increase by 5146.46%. The current median analyst target is $36.72 compared to a current stock price of $0.70. The lowest analysts target is $36.36 and the highest analyst target is $37.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
